EBMT 2026 Highlights | Restoring T-cell Fitness and Enhancing CAR-T Expansion in Bendamustine-Exposed R/R B-NHL

EBMT 2026 Highlights | Restoring T-cell Fitness and Enhancing CAR-T Expansion in Bendamustine-Exposed R/R B-NHL

The 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held from March 22 to 25, 2026, in Madrid, Spain. As one of the most influential international conferences in hematology, EBMT brings together experts worldwide to discuss cutting-edge advances in hematopoietic stem cell transplantation and cellular therapy.
EBMT 2026 China Voice | Professor Xing-Yu Cao: Sequential CD7 CAR-T Followed by Second Transplant Improves Survival to Nearly 50% in Post-Transplant Relapsed T-ALL/LBL

EBMT 2026 China Voice | Professor Xing-Yu Cao: Sequential CD7 CAR-T Followed by Second Transplant Improves Survival to Nearly 50% in Post-Transplant Relapsed T-ALL/LBL

Patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) who relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) have an extremely poor prognosis. Historically, treatment options have been limited, and even with a second transplant, long-term survival has remained below 30%. There is therefore an urgent need for more effective therapeutic strategies.
EBMT 2026 China Voice | Professor Heng Mei: Exploring the Global Frontiers of Cellular Therapy—From In Vivo CAR-T to Technological Innovation

EBMT 2026 China Voice | Professor Heng Mei: Exploring the Global Frontiers of Cellular Therapy—From In Vivo CAR-T to Technological Innovation

At the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2026), held in Madrid, “Cell Therapy Day” emerged as one of the most prominent highlights of the congress. The session brought together leading experts from China, the United States, Germany, and other countries, who shared cutting-edge advances and forward-looking perspectives in cellular immunotherapy. The discussions reflected the rapid and diverse global evolution of this transformative field.
EBMT 2026 China Voice | Professor Xiao-Xia Hu: Refining Risk Stratification and Optimizing Decision-Making—Fusion Gene–Guided Transplant Strategies in CBF-AML 

EBMT 2026 China Voice | Professor Xiao-Xia Hu: Refining Risk Stratification and Optimizing Decision-Making—Fusion Gene–Guided Transplant Strategies in CBF-AML 

From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain, bringing together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy. Key topics included optimization of transplant strategies, infection control, CAR-T therapy, and graft-versus-host disease management.
Voices from China at the EBMT Annual Meeting Prof. Jianping Zhang: High CD34⁺ Cell Dose Significantly Reduces EBV Reactivation and Improves Survival in Pediatric Aplastic Anemia Patients Undergoing UCBT

Voices from China at the EBMT Annual Meeting Prof. Jianping Zhang: High CD34⁺ Cell Dose Significantly Reduces EBV Reactivation and Improves Survival in Pediatric Aplastic Anemia Patients Undergoing UCBT

Pediatric aplastic anemia (AA) patients undergoing umbilical cord blood transplantation (UCBT) face outcomes that are closely tied to the infused cell dose. While recommended CD34⁺ cell doses have been established for hematologic malignancies, no clear standard exists for AA, leaving an important gap in clinical decision-making.
Voices from China at the EBMT Annual Meeting Prof. Peihua Lu / Prof. Yanli Zhao: Long-Term Outcomes of HSCT in Elderly Patients with Hematologic Malignancies—A Single-Center Comparison of Haploidentical, Matched Sibling, and Matched Unrelated Donors

Voices from China at the EBMT Annual Meeting Prof. Peihua Lu / Prof. Yanli Zhao: Long-Term Outcomes of HSCT in Elderly Patients with Hematologic Malignancies—A Single-Center Comparison of Haploidentical, Matched Sibling, and Matched Unrelated Donors

Allogeneic hematopoietic stem cell transplantation (HSCT) in elderly patients with hematologic malignancies remains associated with substantial treatment-related risks. Choosing among haploidentical, matched sibling, and matched unrelated donors remains challenging due to the lack of robust head-to-head comparative data.
Voices from China at the EBMT Annual Meeting Prof. Hui Wang / Prof. Man Chen: CD72 as a Meaningful Marker and Target for MRD Assessment After CD19 CAR-T Therapy in B-ALL

Voices from China at the EBMT Annual Meeting Prof. Hui Wang / Prof. Man Chen: CD72 as a Meaningful Marker and Target for MRD Assessment After CD19 CAR-T Therapy in B-ALL

Although CD19 CAR-T therapy achieves high remission rates in relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), relapse driven by CD19 antigen loss poses a major challenge for MRD monitoring and long-term disease management. Identifying more stable biomarkers has therefore become essential for improving response assessment and prognostic evaluation.
Highlights from the EBMT Annual Meeting / The CAST Strategy for Heavily Pretreated Relapsed/Refractory CNS Lymphoma: A Proof-of-Concept Study

Highlights from the EBMT Annual Meeting / The CAST Strategy for Heavily Pretreated Relapsed/Refractory CNS Lymphoma: A Proof-of-Concept Study

The 52nd EBMT Annual Meeting will be held in Madrid, Spain, from March 22 to 25, 2026. As one of the most prominent international meetings in hematology, EBMT brings together experts worldwide to present advances in hematopoietic stem cell transplantation and cellular therapies, fostering innovation in clinical practice.
Highlights from the EBMT Annual Meeting / Autologous Hematopoietic Stem Cell Transplantation Combined with CAR-T Therapy Significantly Improves Progression-Free Survival in Relapsed/Refractory Central Nervous System Lymphoma

Highlights from the EBMT Annual Meeting / Autologous Hematopoietic Stem Cell Transplantation Combined with CAR-T Therapy Significantly Improves Progression-Free Survival in Relapsed/Refractory Central Nervous System Lymphoma

The 52nd EBMT Annual Meeting will be held in Madrid, Spain, from March 22 to 25, 2026. As one of the most prominent international meetings in hematology, EBMT gathers experts worldwide to discuss cutting-edge advances in hematopoietic stem cell transplantation and cellular therapies, fostering innovation in clinical practice and advancing the field.